Lennon RP, Sakya SM, Miller EL, Snyder B, Yaman T, Zgierska AE, Ruffin 4th MT, Van Scoy LJ. Public intent to comply with COVID-19 public health recommendations. Health Lit Res Pract. 2020 Aug 6;4(3):e161-5. doi: 10.3928/24748307-20200708-01
Block, Jr. R, Berg A, Lennon RP, Miller EL, Nunez-Smith M. African American adherence to COVID-19 public health recommendations. Health Lit Res Pract. 2020 Aug 6;4(3):e166-70. doi: 10.3928/24748307-20200707-01
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.